CAS: 22560-16-3; Lithium Triethylborohydride

上下游产品

CAS号97-94-9 三乙基硼 | CAS号17685-52-8 十二羰基三铁 | CAS号103751-58-2 Fe3(μ3-vinylide... | CAS号112220-75-4 Fe4(μ3-CHCH3)(μ... | CAS号69440-00-2 (μ-H)3Fe3(μ3-CC... | CAS号12136-60-6 硒酸锂 | CAS号1486-28-8 二苯基甲基膦 | CAS号12083-24-8 (甲苯)三羰基铬 | CAS号12081-54-8 tetraethyldiborane

三乙基硼置于正丁基锂体系中,用 四氢呋喃,正戊烷 用作溶剂,以>99的收率获得三乙基硼氢化锂
参考文献:碱金属氢化物的加成化合物:Xviii.三烷基硼烷与叔丁基锂的反应.制备三烷基硼氢化锂的通用便捷方法
标题:碱金属氢化物的加成化合物:Xviii.三烷基硼烷与叔丁基锂的反应.制备三烷基硼氢化锂的通用便捷方法
摘要:考察了叔丁基锂与具有广泛不同空间要求的代表性三烷基硼烷的反应.即使在-78oc下,该反应在醚溶剂中也迅速发生,并以定量收率形成相应的三烷基硼氢化锂.这种合成是高度通用的,甚至包含受强烈阻碍的三烷基硼烷,例如三(反-2-甲基环戊基)硼烷和三唾液酸基硼烷.唯一的副产物是异丁烯,其通常是无害的且易于除去.通过氢化物分析,红外光谱和11对三烷基硼氢化锂进行了表征b NMR谱.三烷基硼氢化物的形成似乎是由于动力学因素,而不是由于热力学因素.该反应为三烷基硼氢化锂提供了一种高度通用,简便且定量的途径.
Doi:10.1016/s0022-328X(00)83693-1

专利信息

专利号:US-11912654-B2
优先权日:2021-09-03
标 题:Process for stereospecific synthesis of vitamin K2 and its novel intermediates
发明人：MEHTA DILIP; SHASHTRI MAYANK; RAJU BNS; SHAH ASHWIN; VORA PARIN; MAHALE UMAKANT
权利人:SYNERGIA LIFE SCIENCES PVT LTD
摘要:The present disclosure relates to a novel process for the synthesis of stereospecific compounds of Vitamin K2 group in general and Vitamin K2-7. The present disclosure further discloses novel intermediates useful in the synthesis of stereospecific Vitamin K2-7. Compounds of the Vitamin K2 group obtained are crystalline and exhibit well defined melting points.

专利号:WO-2023031841-A1
优先权日:2021-09-03
标题:A process for the stereospecific synthesis of vitamin k2 and its intermediates
发明人：MEHTA DILIP; SHASHTRI MAYANK; RAJU BNS; VORA PARIN; MAHALE UMAKANT
权利人:SYNERGIA LIFE SCIENCES PVT LTD
摘要:The present disclosure relates to a novel process for the synthesis of stereospecific compounds of Vitamin K2 group in general and Vitamin K2-7, in particular. It also discloses novel intermediates useful in the synthesis of stereospecific Vitamin K2-7. Compounds of the Vitamin K2 group obtained are crystalline and exhibit well defined melting points.

专利号:US-2025066296-A1
优先权日:2021-12-14
标题 :Methods for the synthesis of complement factor d inhibitors and intermediates thereof
发明人：HASHIMOTO AKIHIRO; PHADKE AVINASH; RAI U SANKAPPA; CHANDRAN PRABU
权利人:ALEXION PHARMA INC
摘要:The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof.

专利号:US-2023183867-A1
优先权日:2020-05-21
标题:Electrochemical synthesis of metal superhydrides
发明人：VISWANATHAN VENKATASUBRAMANIAN; GUAN PIN-WEN
权利人:UNIV CARNEGIE MELLON
摘要:Processes for producing a metal superhydride include obtaining a metal or metal alloy electrode comprising one or more metal atoms, obtaining an electrolyte comprising hydrogen atoms, the electrolyte configured to kinetically suppress a hydrogen evolution reaction in the metal electrode, disposing the metal electrode in the electrolyte, applying pressure to the metal electrode and the electrolyte while the metal electrode is disposed in the electrolyte, and forming, based on applying the pressure, a metal superhydride comprising a plurality of hydrogen atoms of the electrolyte being bonded to each of the one or more metal atoms of the metal electrode. Generally, the metal superhydride is stable at a pressure less than 100 gigapascal (GPa).

专利号:US-12163079-B2
优先权日:2019-08-12
标 题 :Synthesis of blue-emitting ZnSe1-xTex alloy nanocrystals with low full width at half-maximum
发明人：NEWMEYER BENJAMIN; IPPEN CHRISTIAN; MA RUIQING
权利人:SHOEI CHEMICAL IND CO
摘要:The invention pertains to the field of nanotechnology. The invention provides highly luminescent nanostructures, particularly highly luminescent nanostructures comprising a ZnSe 1-x Te x core and ZnS and/or ZnSe shell layers. The nanostructures comprising a ZnSe 1-x Te x core and ZnS and/or ZnSe shell layers display a low full width at half-maximum and a high quantum yield. The invention also provides methods of producing the nanostructures.

专利号:WO-2022256660-A1
优先权日:2021-06-04
标 题:Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
发明人：HARRISON CRISTIAN
权利人:VERTEX PHARMA
摘要:Provided in this application is a process for making Compound I (I) and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels. Processes for making various intermediate products, and suitable salts thereof, are also provided.